|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13.05.26 - 15:03
|
Biofrontera Launches Second Annual “Hats On” Campaign to Raise Awareness of Actinic Keratosis (GlobeNewswire EN)
|
|
|
Woburn, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced the return of the Hats On Campaign for its second consecutive year. Co-founded by Biofrontera in 2025, the community-driven, social media–based initiative will run May 18–24, 2026, culminating on Global AK Awareness Day. The campaign invites participants to wear a hat, post a photo or video, and use the hashtags #HatsOnForAK, #GlobalAKDay, and #ActinicKeratosis to help raise awareness of AK and the critical role of sun protection in preventing the disease....
|
|
|
08.05.26 - 22:03
|
Biofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026 (GlobeNewswire EN)
|
|
|
WOBURN, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces it will report financial results for the three months ended March 31, 2026 after the close of the U.S. financial markets on Thursday, May 14, 2026. The Company will host a conference call on Thursday, May 14, 2026 at 11:00 a.m. Eastern Time to discuss those results, provide a business update and answer questions.Conference Call and Webcast Information...
|
|
|
|
|
|
|
|
|
|
|
|
|
09.03.26 - 22:27
|
Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026 (GlobeNewswire EN)
|
|
|
WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces it will report financial results for the three months and full year ended December 31, 2025 after the close of the U.S. financial markets on Thursday, March 19, 2026. The Company will host a conference call on Thursday, March 19, 2026 at 10:00 a.m. Eastern Time to discuss those results, provide a business update and answer questions....
|
|
|
|
|
|
|
26.02.26 - 15:18
|
U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma′s Patent 11,697,028 To Be Unpatentable (GlobeNewswire EN)
|
|
|
WOBURN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy (“PDT”), today announced that on February 23, 2026, the U.S. Patent Trial and Appeal Board (the “Board”) issued a Final Written Decision finding all challenged claims of Sun Pharmaceutical Industries, Inc.'s U.S. Patent No. 11,697,028 (the “'028 Patent”) to be unpatentable....
|
|
|
|
|
|
|
11.02.26 - 15:18
|
Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma (GlobeNewswire EN)
|
|
|
WOBURN, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy (PDT), today announced that the U.S. Food and Drug Administration (FDA) has completed its filing review and accepted filing of the Company's supplemental New Drug Application (sNDA) for Ameluz® (aminolevulinic acid hydrochloride) topical gel used in combination with the RhodoLED® red-light lamp series for the treatment of sBCC. The FDA identified no filing deficiencies and assigned a PDUFA target action date of September 28, 2026....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
